A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients"INTERVENTIONAL
Timeline

Start Date

March 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 24, 2012

Conditions
Parkinson Disease
Interventions
DRUG

Safinamide

"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."

Trial Locations (1)

06510

Molecular Neuroimaging, LLC, New Haven

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT01264861 - A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging | Biotech Hunter | Biotech Hunter